Clinical guide to feline hepatic lipidosis (fatty liver). Learn the diagnostic workup (ALP-to-GGT ratio, liver FNA), feeding tube stabilization, and refeeding syndrome mitigation.

Feline hepatic lipidosis (HL), commonly referred to as fatty liver disease, is one of the most common and clinically severe hepatobiliary disorders in domestic cats. Characterized by the massive accumulation of triglycerides within hepatocytes, this syndrome leads to intrahepatic cholestasis, progressive hepatic dysfunction, and, if untreated, hepatic failure and death. The metabolic pathway of hepatic lipidosis is uniquely pronounced in cats compared to other mammals.

For veterinary professionals, managing hepatic lipidosis is a exercise in metabolic stabilization, clinical nutrition, and intensive care nursing. For cat owners, it is a high-stakes, emotionally taxing journey that frequently requires managing an enteral feeding tube at home for several weeks.

This clinical guide reviews the pathophysiology of feline hepatic lipidosis, details the diagnostic sequence—emphasizing key laboratory markers like the alkaline phosphatase (ALP) to gamma-glutamyl transferase (GGT) ratio—outlines stabilization protocols, compares enteral feeding options, and provides a structured nursing care framework for the general practice clinic and the home environment.

Quick answer

What is feline hepatic lipidosis, how is it diagnosed, and what is the survival rate?

Feline hepatic lipidosis is a liver emergency triggered by a period of anorexia (typically 3 to 7+ days), causing rapid mobilization of body fat stores to the liver.

Diagnosis relies on clinicopathology (marked ALP elevation, hyperbilirubinemia, but normal or mildly elevated GGT), abdominal ultrasound (a diffusely bright/hyperechoic liver), and liver fine-needle aspiration (FNA) cytology confirming lipid vacuoles in >80% of hepatocytes.
Treatment requires early, aggressive enteral nutrition (usually via an esophagostomy tube or E-tube) for 4 to 8 weeks, alongside fluid therapy and electrolyte monitoring.
Prognosis is excellent, with a 85% to 90% survival rate when enteral nutrition is initiated early, before severe liver failure or coagulation crises develop, and when concurrent diseases (e.g., pancreatitis or IBD) are managed.

Pathophysiology: Why cats are uniquely susceptible

To understand why a cat that stops eating develops liver failure, one must look at the unique metabolic adaptations of the feline species. Cats are obligate carnivores, meaning their metabolic pathways are configured for a continuous intake of high-protein, moderate-fat diets. They have a constant, non-adaptive requirement for amino acids and lack the ability to down-regulate urea cycle enzymes during periods of protein deprivation.

[Anorexia / Caloric Deprivation]
              │
              ▼
[Rapid Mobilization of Peripheral Lipids]
              │
              ▼
[Inflow of Free Fatty Acids (FFAs) to Hepatocytes]
              │
              ▼
[Impaired Beta-Oxidation]  ◀─── [Deficiency in Protein, Carnitine, Taurine]
              │
              ▼
[Accumulation of Triglycerides in Liver Cells]
              │
              ▼
[Hepatocellular Swelling & Intrahepatic Cholestasis]
              │
              ▼
[Hepatic Dysfunction / Liver Failure]

When a cat experiences anorexia, it enters a state of negative energy balance. In response, the body mobilizes peripheral lipid stores, flooding the systemic circulation with free fatty acids (FFAs). These FFAs are taken up by hepatocytes. In most mammals, the liver processes these fatty acids through beta-oxidation (to produce energy) or repackages them into very-low-density lipoproteins (VLDLs) for export back into the circulation.

Cats, however, have several metabolic bottlenecks that hinder this process:

Impaired VLDL Export: The pathway for synthesis and secretion of VLDLs in cats is easily saturated. VLDL export requires specific apoproteins, which rapidly become depleted during protein starvation.
Relative Carnitine Deficiency: Carnitine is required to transport long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. While cats can synthesize carnitine from lysine and methionine, active anorexia limits the availability of these precursor amino acids, causing a functional carnitine deficiency.
Essential Amino Acid Deprivation: Carnivores require high amounts of methionine, taurine, and arginine. Methionine and taurine are critical for glutathione synthesis and bile acid conjugation. Deprivation rapidly leads to oxidative stress within hepatocytes, exacerbating liver injury.

As a result of these bottlenecks, the rate of triglyceride synthesis in the hepatocyte cytoplasm far exceeds the rate of beta-oxidation and VLDL export. Triglyceride droplets accumulate within the cells, swelling the hepatocytes. This swelling compresses the adjacent bile canaliculi, leading to intrahepatic cholestasis, mechanical bile duct obstruction, progressive liver dysfunction, and systemic icterus.

Obesity as a primary predisposing factor

While hepatic lipidosis can occur in cats of any body condition, overweight and obese cats are significantly predisposed. Obese cats possess larger peripheral fat stores. When anorexia is triggered, the volume of FFAs mobilized and sent to the liver is vastly greater than in a lean cat, accelerating hepatocellular lipid accumulation. Obese cats also tend to have higher baseline insulin resistance, which further promotes lipolysis in peripheral adipose tissue during stress or fasting.

Underlying triggers: Primary vs. secondary lipidosis

Hepatic lipidosis is classified into two forms:

Primary (Idiopathic) Hepatic Lipidosis: Occurs without an identifiable underlying medical illness. The proportion of cases that are truly idiopathic varies widely by series — reported from roughly 5% up to about 50% — and falls as cases are worked up more thoroughly. It is typically triggered by a sudden environmental stressor that leads to voluntary anorexia, such as moving to a new home, the addition of a new pet, boarding, or a sudden change to an unpalatable diet.
Secondary Hepatic Lipidosis: Occurs as a direct consequence of a primary disease that causes anorexia, vomiting, or malabsorption. It is the majority of cases — commonly cited from about half up to more than 90% depending on case selection and depth of workup. Identifying and treating the secondary trigger is essential for clinical success.

Trigger Category	Specific Diseases	Pathophysiologic Connection
Gastrointestinal	Inflammatory Bowel Disease (IBD), Intestinal Lymphoma, Severe Constipation/Obstipation	Chronic nausea, abdominal pain, and malabsorption drive prolonged voluntary anorexia.
Pancreatic & Biliary	Acute/Chronic Pancreatitis, Cholangiohepatitis (often presenting as "Triaditis")	Direct inflammatory extension to the liver and biliary tract, causing profound nausea and localized ileus. See the pancreatitis in cats diagnosis and treatment guide for the workup of this common co-trigger.
Endocrine	Diabetes Mellitus, Hyperthyroidism	Altered lipid metabolism, insulin deficiency/resistance, and high metabolic demand accelerate lipolysis.
Renal	Chronic Kidney Disease (CKD)	Uremic toxins cause stomatitis, gastritis, oral ulceration, and persistent uremic nausea. CKD-related inappetence and weight loss are covered in detail in the feline CKD treatment guide.
Infectious/Neoplastic	Feline Leukemia Virus (FeLV), Feline Immunodeficiency Virus (FIV), Systemic Neoplasia	Systemic inflammatory response, cytokine release (TNF-alpha), and cachexia drive muscle wasting and anorexia.

Clinical presentation and physical findings

Cats presenting with hepatic lipidosis typically exhibit a consistent history and set of physical findings. The typical patient is a middle-aged (median age 5–7 years) cat with a history of being overweight, followed by a stressful event or illness, leading to a period of anorexia lasting from 3 to 14 days.

Key clinical signs reported by owners include:

Anorexia: Complete or partial refusal of food.
Rapid Weight Loss: Loss of 20% to 40% of baseline body weight is common, often characterized by a loss of muscle mass over the epaxial muscles, while the abdominal fat pad may remain relatively preserved.
Lethargy and Depression: Due to dehydration, electrolyte depletion, and potential hepatic encephalopathy.
Vomiting and Salivation: Hypersalivation is common and often indicates nausea or hepatic encephalopathy (due to hyperammonemia).
Diarrhea or Constipation: Secondary to gastrointestinal dysmotility.

On physical examination, the veterinary team typically observes:

Icterus (Jaundice): Yellow discoloration of the sclera, mucous membranes, and non-pigmented skin, present in over 70% of clinically affected cats.
Hepatomegaly: The liver is palpably enlarged, with smooth, non-painful margins extending beyond the costal arch.
Dehydration: Tacky mucous membranes, prolonged skin tent, and sunken eyes.
Muscle Wasting: Prominent spine and pelvis (cachexia) contrasting with a persistent inguinal fat pad.
Neck Ventroflexion: In severe cases, hypokalemia (potassium depletion) or thiamine (Vitamin B1) deficiency can cause profound cervical muscle weakness, preventing the cat from raising its head.

Diagnostic workup and clinicopathology

A thorough diagnostic workup is required to confirm hepatic lipidosis, rule out other primary hepatobiliary diseases, and identify concurrent triggers.

1. Blood Chemistry: The ALP-vs-GGT diagnostic marker

The serum chemistry profile provides the strongest diagnostic indicator for hepatic lipidosis, characterized by a highly specific pattern of liver enzyme elevations.

Alkaline Phosphatase (ALP): Characterized by marked, often dramatic elevations. ALP levels are typically 5 to 10+ times the upper reference limit (often >500 U/L to 2,000+ U/L). The feline half-life of ALP is extremely short (approx. 6 hours), making any significant elevation highly clinically relevant.
Gamma-Glutamyl Transferase (GGT): In contrast to the massive increase in ALP, GGT is typically normal or only mildly elevated in primary hepatic lipidosis. GGT is a marker of biliary epithelial hyperplasia and extrahepatic biliary obstruction. Because hepatic lipidosis is an intrahepatic cholestatic process where swelling hepatocytes compress canaliculi, the biliary epithelium itself is not primary damaged, leaving GGT low.
Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST): Mildly to moderately elevated (typically 2 to 5 times normal) due to hepatocyte swelling and cell membrane leakage.
Total Bilirubin: Marked hyperbilirubinemia is standard. Bilirubin values frequently exceed 3 to 15+ mg/dL (normal is <0.5 mg/dL), correlating with visible tissue icterus.
Cholesterol: Often elevated due to altered lipid transport.
Blood Urea Nitrogen (BUN) and Creatinine: BUN is often low or low-normal due to decreased protein intake and reduced urea synthesis by the dysfunctional liver, unless concurrent renal disease or severe dehydration (prerenal azotemia) is present.

[!IMPORTANT] The ALP-to-GGT Ratio: A patient presenting with a marked elevation in ALP alongside a normal or minimally elevated GGT is highly indicative of hepatic lipidosis. If both ALP and GGT are markedly elevated, the clinician must prioritize primary cholangiohepatitis, biliary cystadenoma, or extrahepatic bile duct obstruction (EHBDO) in the differential diagnosis.

2. Complete Blood Count (CBC) and Coagulation

Non-Regenerative Anemia: Often present due to chronic disease or mild hemolysis.
Poikilocytosis: High numbers of abnormal red blood cell shapes, specifically Heinz bodies (oxidative damage) and target cells (codocytes), which occur due to alterations in erythrocyte membrane lipid composition.
Coagulation Profile (PT and aPTT): Prolonged PT and aPTT are common. The liver synthesizes coagulation factors (I, II, V, VII, IX, X, XI, XII). Bile acid deficiency due to intrahepatic cholestasis impairs the absorption of fat-soluble vitamins, specifically Vitamin K1, which is required for the activation of factors II, VII, IX, and X.

3. Abdominal Ultrasound

Abdominal ultrasound is the imaging modality of choice. The classic ultrasonographic appearance of hepatic lipidosis includes:

Diffuse Hepatomegaly: The liver lobes are enlarged with rounded margins.
Diffuse Hyperechogenicity: The liver parenchyma appears hyperechoic (bright) compared to the surrounding falciform fat and the renal cortex. The normal liver is typically hypoechoic or isoechoic to the spleen and renal cortex; in lipidosis, it is markedly brighter, often causing distal acoustic enhancement (the ultrasound beam penetrates deeply due to the lipid content).
Normal Biliary Tree: The extrahepatic bile ducts and gallbladder are typically normal in size and free of obstruction, ruling out extrahepatic biliary tract disease.

4. Liver Cytology (Fine-Needle Aspirate)

A definitive diagnosis is confirmed by cytological evaluation of a liver fine-needle aspirate (FNA).

Procedure: Performed under ultrasound guidance, typically without sedation unless the cat is highly fractious. A 22-gauge or 25-gauge needle is used to obtain aspirates from multiple lobes.
Cytological Findings: Smears show sheets of hepatocytes containing clear, well-defined cytoplasmic vacuoles of varying sizes (macro- and microvesicular vacuolization). When these vacuoles push the hepatocyte nucleus to the periphery, it confirms severe lipid accumulation. Cytology is considered diagnostic when more than 80% of hepatocytes are vacuolated.
Biopsy Caution: True histopathological biopsy (tru-cut or surgical) is rarely performed in acute hepatic lipidosis. Fatty livers are highly friable, and these patients have a high risk of hemorrhage. Biopsy should be avoided unless cytology is inconclusive and a coagulation profile has confirmed normal clotting times.

Stabilization and medical management

A cat presenting in a hepatic lipidosis crisis cannot immediately undergo feeding tube placement. They are typically dehydrated, acidotic, nauseous, and suffering from electrolyte imbalances that make anesthesia dangerous. Initial stabilization requires 12 to 36 hours of intensive medical therapy.

The drug doses and fluid-electrolyte ranges below are summarized from published feline guidelines and labels for professional reference only; they are not a prescription. Doses must be individualized to the patient's weight, electrolytes, and comorbidities and confirmed against the current product label before administration.

1. Fluid Therapy and Electrolyte Correction

Intravenous fluid therapy must be tailored to correct dehydration and address specific electrolyte deficits.

Fluid Choice: Balanced crystalloids, such as Balanced Salt Solutions (e.g., Plasma-Lyte or Normosol-R) or Lactated Ringer's Solution (LRS).
Avoid Dextrose Initially: Do not add dextrose to the fluid plan during initial stabilization. Flooding an anorexic, insulin-resistant patient with glucose triggers insulin release, which drives potassium and phosphorus into the cells, precipitating a life-threatening electrolyte crash (refeeding syndrome).
Potassium Supplementation: Hypokalemia is present in the majority of these patients due to anorexia and urinary wasting. Potassium chloride (KCl) must be added to the fluid bag based on measured serum potassium levels. Profound hypokalemia (<2.5 mmol/L) leads to generalized muscle weakness, neck ventroflexion, respiratory failure, and cardiac arrhythmias.
Phosphorus Monitoring: Hypophosphatemia is a critical risk. If serum phosphorus drops below 1.5 mg/dL (0.48 mmol/L), intravascular hemolysis occurs, leading to hemolytic anemia, weakness, and seizure activity. Potassium phosphate (KPO₄) may be used to supplement phosphorus, replacing a portion of the calculated KCl requirement.

Serum Potassium (mmol/L)	KCl Supplementation (mEq/L of fluids)	Max Infusion Rate
3.5 – 5.5 (Normal)	20 mEq/L	Do not exceed 0.5 mEq/kg/hour
3.0 – 3.4	30 mEq/L	Do not exceed 0.5 mEq/kg/hour
2.5 – 2.9	40 mEq/L	Do not exceed 0.5 mEq/kg/hour
< 2.5	60 – 80 mEq/L	Continuous ECG monitoring required

2. Antiemetic Therapy and Nausea Control

Nausea is a primary driver of anorexia. It must be controlled aggressively to facilitate future enteral feeding.

Maropitant (Cerenia): Neurokinin-1 (NK₁) receptor antagonist. Administered at 1 mg/kg IV or SC once daily. Maropitant provides central and peripheral antiemetic effects and has visceral analgesic properties.
Ondansetron: 5-HT₃ receptor antagonist. Administered at 0.5 mg/kg IV or PO two to three times daily. Often used in combination with maropitant in cats with refractory vomiting or severe pancreatitis.

3. Coagulation Support: Vitamin K1

Due to fat-soluble vitamin malabsorption, vitamin K1 deficiency must be assumed.

Vitamin K1 (Phytonadione): Administered at 0.5 to 1.5 mg/kg SC upon presentation. A second dose should be given 12 to 24 hours later, prior to any invasive procedures like E-tube placement or liver aspirates. Avoid intramuscular (IM) administration due to the risk of hematoma formation.

4. Hepatoprotective and Metabolic Supplements

Cobalamin (Vitamin B12): Almost all cats with chronic GI or liver disease are cobalamin depleted. Administer 250 mcg SC once weekly for 4 to 6 weeks. Cobalamin deficiency impairs cellular metabolism and exacerbates anorexia.
S-Adenosylmethionine (SAMe): Sourced as a hepatoprotectant. SAMe is a precursor to glutathione, the liver's primary antioxidant. Administer PO on an empty stomach. Since oral administration can be difficult in nauseous cats, it is often started via the feeding tube once placed.
L-Carnitine: Facilitates transport of fatty acids into mitochondria. Administer 250 to 500 mg PO once daily.
Thiamine (Vitamin B1): Essential for carbohydrate metabolism. Deficiency causes neurological signs (dilated pupils, ventroflexion, ataxia). Administer 50 to 100 mg IM or SC once daily for the first few days of stabilization.

Enteral nutrition: Esophagostomy tubes (E-tubes)

The single most important treatment for hepatic lipidosis is food. Voluntary food intake is rarely successful in reversing the fat mobilization cascade; force-feeding is contraindicated because it causes food aversion and increases the risk of aspiration pneumonia. Enteral feeding tubes are required.

Esophagostomy Tube (E-Tube) vs. Gastrostomy (G-Tube) and Nasoesophageal (NE-Tube)

Nasoesophageal (NE) / Nasogastric (NG) Tubes: Useful only for short-term stabilization (1 to 5 days) in the clinic. Because of their small diameter (typically 3.5 to 5 French), they can only accommodate thin liquid diets, clog easily, and are uncomfortable for long-term home use.
Gastrostomy (G) Tubes: Placed surgically or endoscopically directly into the stomach. They can remain in place for months and accommodate blenderized diets. However, they require specialized equipment for placement, have a mandatory 10–14 day wait before removal to allow a stoma to form, and carry a risk of peritonitis if displaced.
Esophagostomy (E) Tubes: The preferred clinical standard for hepatic lipidosis. They are placed under brief general anesthesia into the mid-cervical esophagus, require no specialized endoscopic equipment, accommodate standard blenderized recovery diets (using 14 to 19 French tubes), can be removed at any time without waiting for stoma consolidation, and are well-tolerated by cats in the home environment.

                  [Esophagostomy Tube (E-Tube) Overview]
                     
         Tube Entry (Left Mid-Neck) ──┐
                                      │  Securely sutured with finger-trap pattern
                                      ▼
                   [Esophagus] ───────○─── [Stomach]
                                        (Tube tip sits in distal esophagus,
                                         proximal to gastroesophageal sphincter)

E-Tube Placement Procedure Key Steps

Patient Position: Right lateral recumbency under general anesthesia. The left side of the neck is clipped and prepared aseptically.
Instrument Guidance: A curved carmalt clamp is inserted through the mouth into the esophagus, with the tip directed outward against the left mid-cervical esophageal wall.
Incision: A small skin incision is made over the bulged tip of the carmalt clamp. The instrument is pushed through the esophageal wall and out through the skin incision.
Tube Insertion: A red rubber or silicone E-tube (typically 14 French for average cats, 18 French for larger cats) is grasped by the clamp, pulled down into the esophagus, and out through the mouth.
Redirecting the Tube: The oral portion of the tube is grasped and redirected back down the esophagus, so the tip sits in the distal thoracic esophagus (just cranial to the lower esophageal sphincter).
Securing the Tube: Position is verified by palpation and lateral thoracic radiography. The tube is secured to the skin using a Chinese finger-trap suture pattern and covered with a light wrap.

Feeding protocol and refeeding syndrome mitigation

Feeding must begin slowly. The liver is congested, metabolic pathways are depleted, and the GI tract has been dormant.

1. Diet Selection

The diet must be high-protein, high-fat, and calorie-dense. The industry standard is a canned veterinary recovery diet (such as Hill's Prescription Diet a/d or Royal Canin Veterinary Diet Recovery). These diets are easily blenderized with warm water and strained to pass through a 14 Fr or 18 Fr E-tube.

2. Calculating the Nutritional Plan

Resting Energy Requirement (RER): Calculated using the formula RER = 70 × (current body weight in kg)^0.75. Alternatively, for cats weighing between 2 kg and 25 kg, a close linear approximation is RER = [30 × (body weight in kg)] + 70.
Refeeding Mitigation Schedule: Never feed 100% of the RER on Day 1. This triggers an insulin spike, driving potassium, phosphorus, and magnesium into the intracellular space, causing hypokalemia, hypophosphatemia, and acute hemolytic anemia.

Day of Feeding	Target Caloric Intake	Feeding Frequency	Feeding Volume Example (100% Labeled Diet)
Day 1	33% (1/3) of RER	Divided into 4 to 6 meals	Warm water flushes prior to feeding; feed slowly over 10-15 minutes.
Day 2	66% (2/3) of RER	Divided into 4 to 6 meals	Monitor serum potassium and phosphorus prior to increasing.
Day 3	100% of RER	Divided into 3 to 4 meals	Maintained at this level for the duration of recovery.

3. Step-by-Step Enteral Feeding Technique

To prevent vomiting, volume overload, and tube occlusion:

Prepare the Feed: Blenderize the calculated portion of recovery diet with warm water. Ensure the mixture is at room or body temperature; cold food triggers esophageal spasm and vomiting.
Verify Tube Patency: Flush the E-tube with 5 to 10 mL of warm water before feeding. Feel the neck to ensure there is no swelling or pain, which would indicate leakage.
Feed Slowly: Inject the food syringe through the tube port slowly, taking 10 to 15 minutes to deliver the meal. Rapid feeding stretches the stomach, leading to acute vomiting.
Post-Feed Flush: Flush the tube with 5 to 10 mL of warm water to clear any remaining food debris from the lumen, preventing bacterial growth and tube occlusion. Cap the tube port.
Monitor: Check for lip-licking, salivation, or restlessness during and after feeding, which are signs of nausea. If observed, stop feeding, wait 30 minutes, and consult the vet team for adjustment of antiemetics.

E-tube home care and troubleshooting matrix

Once the cat is stabilized, tolerating 100% RER, and their electrolytes are stable, they can be discharged to the owner's care. Success at home depends on clear client education and troubleshooting protocols.

Complication	Clinical Signs	Immediate Action / Prevention
Refeeding Syndrome	Weakness, pale mucous membranes (hemolysis), rapid breathing, seizures, sudden collapse.	Occurs within the first 1-4 days of refeeding. Stop feeding immediately and return to the hospital for intravenous electrolyte support and bloodwork.
Stoma Site Infection	Redness, swelling, purulent discharge, foul odor, or pain around the neck incision.	Inspect the stoma daily. Clean gently with warm water or dilute chlorhexidine. Apply a clean dressing. If infection is suspected, contact the vet for oral antibiotic therapy (e.g. Clavamox).
Tube Occlusion (Clogging)	Inability to flush water or inject food through the tube port.	Never use force. Try flushing with warm water using a smaller (3 mL) syringe to exert higher pressure. Alternatively, instill a solution of warm water and pancreatic enzymes or a small amount of carbonated water (coca-cola) and let sit for 20 minutes before flushing.
Tube Displacement / Vomiting	Cat vomits the tube; the tube is visible coming out of the mouth, or the external length is significantly longer.	Keep the cat calm. Do not use the tube. Bandage the neck lightly and bring the cat to the clinic. The tube must be repositioned under light sedation or removed.
E-Tube Removal by Cat	The cat claws at the wrap, dislodging the tube; sutures are torn.	Apply a clean, dry wrap over the neck wound. Bring the cat to the clinic. esophagostomy stomas heal rapidly by second intention (typically within 3-5 days) without primary closure.

Prognosis and recovery milestones

The prognosis for feline hepatic lipidosis has improved dramatically over the last few decades. Historically, mortality rates approached 90%. Today, with early diagnostics and aggressive enteral feeding tube management, survival and cure rates are between 85% and 90%.

1. Recovery Timeline

Weeks 1 to 2: Stabilization, tube placement, and initiation of 100% RER. Liver enzymes remain high; bilirubin levels may begin to plateau.
Weeks 3 to 4: Bilirubin levels show a steady decline (often dropping by 50% or more). Hepatomegaly decreases. The cat may begin to show interest in food.
Weeks 5 to 8: Voluntary food intake increases. E-tube feeding is gradually reduced as the cat meets its caloric requirements on its own.

2. Criteria for E-Tube Removal

The E-tube should not be removed until the following milestones are met:

Voluntary Caloric Intake: The cat must eat 100% of its calculated RER voluntarily for 7 consecutive days.
Stable Weight: The cat must maintain its body weight during the trial week when tube feedings are reduced.
Laboratory Improvements: Bilirubin must be normal or near-normal (<1.5 mg/dL), and liver enzymes must be significantly improved.
Resolved Comorbidities: Any secondary triggers (e.g., pancreatitis flare-up or IBD signs) must be controlled.

If these criteria are met, the E-tube is removed in the clinic. The stoma site is cleaned, a light bandage is applied for 24 hours, and the wound is allowed to heal by second intention.

Frequently asked questions

Can a cat recover from hepatic lipidosis without a feeding tube?

In very mild, early cases caught immediately, a cat might recover with aggressive antiemetic therapy, fluid support, and appetite stimulants (such as the Mirataz vs. Elura options compared here). However, for clinically significant cases (visible jaundice, marked ALP elevation), recovery without a feeding tube is highly unlikely. Syringe-feeding is stressful, increases food aversion, and rarely delivers the required 100% RER, leading to a high failure rate.

How long does it take for a cat to recover from fatty liver disease?

Most cats require a feeding tube for 4 to 8 weeks. The liver needs time to clear the accumulated triglycerides, regenerate damaged hepatocytes, and re-establish normal bile flow. Attempting to remove the tube too early (e.g., after 2 weeks) frequently results in relapse.

Is fatty liver disease in cats painful?

The primary liver lipidosis process is not considered highly painful, though the liver capsule stretching can cause mild abdominal discomfort. However, the secondary diseases that trigger lipidosis (such as pancreatitis or cholangiohepatitis) are often highly painful and require appropriate analgesia (e.g., buprenorphine).

Will hepatic lipidosis return once the cat is cured?

Once fully recovered, cats rarely relapse unless they experience another prolonged period of anorexia due to stress or secondary illness. The liver does not suffer permanent scarring or cirrhosis from lipidosis, allowing for complete structural and functional recovery.

Sources

Merck Veterinary Manual: Feline Hepatic Lipidosis Clinical Overview
Cornell Feline Health Center: Hepatic Lipidosis Health Guide
Veterinary Information Network (VIN): Feline Hepatic Lipidosis Diagnostics and Treatment Protocols
Journal of Veterinary Internal Medicine (JVIM): ACVIM Consensus Statements on Feline Hepatobiliary Diseases.

Vet Med Guide

Feline Hepatic Lipidosis: Why a Cat Stopped Eating Becomes a Liver Emergency